DWP 306001
Alternative Names: DWJ-306; DWP-306001; Enavogliflozin + DWC202010Latest Information Update: 12 Feb 2024
At a glance
- Originator Daewoong Pharmaceutical
- Class Benzofurans; Cyclopropanes; Obesity therapies; Small molecules
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Obesity
Most Recent Events
- 06 Feb 2024 Daewon Pharmaceutical plans a phase II trial for Obesity in 2024
- 10 Feb 2022 DWP 306001 is available for licensing as of 09 Feb 2022. https://www.daewoong.com/en/company/location/4/view
- 09 Feb 2022 Phase-I clinical trials in Obesity in South Korea (unspecified route) (Daewoong Pharmaceuticals pipeline, February 2022)